Basic Information (Switzerland) Elecon Asia SA (hereinafter referred to as “Elecon”) is a powerful intelligent three-d...
Digital Copyright Ten Major Typical Cases 1.Short Video Copyright Case: Whether a Short Video is Original Has Nothing to...
December 7, 2023 - News of a patent infringement ruling against Apple Watches a few weeks ago caused a flurry of investo...
's claim in the dispute over Targin. For years, Frankfurt-based Mundipharma defended market exclusivity for its painkiller Targin against various generic drug manufacturers. The product combines two
Context: Semaglutide (glp-1 receptor) is the active ingredient found in Ozempic, a Novo Nordisk drug used for the treatment of type 2 diabetes that generated global sales of approximately $13.9
the effective approval date of MSN’s generic drug until after November 9, 2026. June 10, 2025: MSN responded to that letter, claiming Novartis “essentially re-packaged its post-trial brief.”
Generic drug companies cannot launch their enzalutamide products in the Netherlands. In the pan-European dispute over prostate cancer drug Xtandi, the District Court The Hague upheld a basic patent
total 1 pages, 4 items
CHINA intellectual PROPERTY LAWYERS NETWORK
+86-13910160652
ciplawyers@163.com
